Enterprise Value
218.4M
Cash
75.28M
Avg Qtr Burn
-3.119M
Short % of Float
0.25%
Insider Ownership
0.00%
Institutional Own.
19.76%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NBTXR3 +/- Cetuximab Details Head and neck cancer, Cancer | Phase 3 Interim Update | |
RT + NBTXR3 + Chemotherapy Details Cancer, Esophageal cancer | Phase 1/2 Data readout | |
RT + NBTXR3 Details Cancer, Pancreatic cancer | Phase 1b Data readout | |
NBTXR3 + Anti-PD-1 Details Head and neck cancer, Cancer, Non-small cell lung carcinoma, Solid tumor/s | Phase 1 Data readout | |
RT + NBTXR3 Details Cancer, Non-small cell lung carcinoma | Phase 1 Data readout |